Complete SARMs Guide (2026): Research Overview for Canada (Plus MK-677, GW-501516 & SR9009)

Table of Contents

  1. What are SARMs?

  2. How SARMs work (simple mechanism overview)

  3. SARMs vs anabolic steroids (high-level comparison)

  4. Commonly discussed SARMs (research context)

  5. Commonly bundled “SARM-adjacent” compounds: MK-677, GW-501516, SR9009

  6. Documentation in research supply chains (COA basics)

  7. FAQ (Canada, 2026)

  8. Sources and evidence limitations

1) What are SARMs?

SARMs (Selective Androgen Receptor Modulators) are a class of synthetic compounds designed to interact with the androgen receptor (AR), with the original drug-development goal of creating more selective androgen-receptor activity than traditional anabolic-androgenic steroids.

2) How SARMs work (mechanism overview)

At a high level, SARMs are designed to:

  • Bind the androgen receptor (AR) and influence androgen-signaling pathways

  • Aim for functional selectivity across tissues (a design goal often discussed in the literature and product marketing)

3) SARMs vs anabolic steroids (high-level comparison)

Both SARMs and anabolic-androgenic steroids (AAS) relate to androgen signaling, but they differ in how they were engineered and how they are commonly categorized:

  • AAS: steroidal structures, long-established history of medical and non-medical use

  • SARMs: non-steroidal structures (in most cases), designed to modulate AR signaling with a “selective” intent

4) Commonly discussed SARMs (research context)

These are some of the most frequently referenced SARMs in online research discussions and market listings:

5) Commonly bundled “SARM-adjacent” compounds (not SARMs)

A lot of “SARMs” catalogs include compounds that are not SARMs, but are frequently discussed alongside them. The three most common are:

MK-677 (Ibutamoren) — not a SARM

  • Often grouped with SARMs in product catalogs, but it is typically described as a growth hormone secretagogue in scientific discussion (not an androgen receptor modulator).

GW-501516 (Cardarine) — not a SARM

  • Commonly described as a PPARδ agonist, frequently sold in the same ecosystem as SARMs, but it is not a selective androgen receptor modulator.

SR9009 — not a SARM

  • SR9009 was initially characterized as a synthetic REV-ERB agonist in preclinical research. Later knockout experiments found that some effects persisted without REV-ERBα/β, so its mechanism should not be presented as settled; these preclinical studies do not establish human safety or efficacy.

6) Documentation in research supply chains (COA basics)

In legitimate chemical and research supply chains, it’s common to see documentation such as:

  • Certificate of Analysis (COA) (e.g., identity/purity summaries, method references)

For a practical, Canada-focused checklist, see our guide to evaluating COAs, identity, purity, concentration, and material-lot traceability.

This guide does not evaluate any supplier and does not provide procurement guidance; it’s simply an overview of documentation types commonly referenced in research contexts.

7) FAQ (Canada, 2026)

What are SARMs in simple terms?

SARMs (Selective Androgen Receptor Modulators) are compounds studied for how they interact with the androgen receptor (AR). In research discussions, they’re often used as a lens to explore androgen signaling, receptor binding, and downstream biological pathways.

What does “selective” mean with SARMs?

“Selective” usually refers to the idea that different compounds may produce different patterns of receptor activity depending on tissue context, signaling pathways, and molecular structure. In research terms, it’s about how a compound modulates receptor activity.

Which SARMs are most commonly referenced in research discussions?

In the broader research and enthusiast ecosystem, the most commonly referenced SARMs include:

  • MK-2866 (Ostarine / Enobosarm)

  • LGD-4033 (Ligandrol)

  • RAD-140 (Testolone). These show up frequently because they’re widely discussed as “core” AR modulators in many SARMs overviews. For the compound’s first published human evidence, see our analysis of the 22-patient phase 1 RAD-140 trial.

Marketing labels do not establish physique outcomes; our “cutting” claims evidence review separates human, animal, and mechanistic findings.

Are MK-677, GW-501516 (Cardarine), and SR9009 SARMs?

No—these are not SARMs, but they’re often discussed in the same circles:

  • MK-677 (Ibutamoren) is generally described as a growth hormone secretagogue.

  • GW-501516 (Cardarine) is generally described as a PPARδ agonist.

  • SR9009 was initially characterized in preclinical research as a synthetic REV-ERB agonist, but later knockout experiments found that some effects persisted without REV-ERBα/β. It is not a SARM, and the preclinical evidence does not establish human safety or efficacy.

Why do people group SARMs with MK-677 / Cardarine / SR9009?

Because many people search “SARMs” as shorthand for the entire research-compound ecosystem. A helpful mental model is:

  • SARMs → primarily AR-focused discussion

  • MK-677 / GW-501516 / SR9009 → different targets, often discussed alongside SARMs for category overlap in catalogs and forums

What’s the best way to compare products across compounds?

For a clean apples-to-apples comparison in a research context, focus on:

  • Total amount (e.g., total mg per bottle/vial)

  • Concentration (e.g., mg/mL for solutions)

  • COA documentation fields (what’s documented and which method is referenced)

Catalogue cross-reference

For exact product formats and concentrations, review the individual listings for RAD-140, MK-2866 (Ostarine), LGD-4033, MK-677, GW-501516 (Cardarine), and SR9009. You can also compare all research solutions and research stacks.

8) Sources and evidence limitations

Human evidence for the compounds discussed here is not a single, interchangeable body of evidence. Studies differ by compound, dose, population and duration; several are small or short, and preclinical findings do not establish human safety or efficacy. Health Canada states that SARMs have not been authorized in Canada for any medical use. WADA’s prohibited status is an anti-doping rule, not evidence of medical approval or benefit.

  1. Health Canada. Using bodybuilding products. Government of Canada; updated May 14, 2026.
  2. Health Canada. Unauthorized products may pose serious health risks (December 9, 2019 to January 17, 2020). Government of Canada; updated February 10, 2020.
  3. U.S. Food and Drug Administration. FDA Warns of Use of Selective Androgen Receptor Modulators (SARMs) Among Teens, Young Adults.
  4. World Anti-Doping Agency. 2026 List of Prohibited Substances and Methods. Effective January 1, 2026.
  5. Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87–95. doi:10.1093/gerona/gls078.
  6. Ooi EMM, Watts GF, Sprecher DL, Chan DC, Barrett PHR. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab. 2011;96(10):E1568–E1576. doi:10.1210/jc.2011-1131.
  7. Solt LA, Wang Y, Banerjee S, et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. 2012;485(7396):62–68. doi:10.1038/nature11030.
  8. Dierickx P, Emmett MJ, Jiang C, et al. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. Proc Natl Acad Sci U S A. 2019;116(25):12147–12152. doi:10.1073/pnas.1904226116.

Sources accessed August 23, 2026. These references summarize regulatory context and selected evidence; they do not verify any supplier, product, material lot, or finished solution.

Shopping Cart
Scroll to Top
Cart (0 items)$0.00Checkout